ReproCELL Incorporated
4978
Rank in Stocks
#21003
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL... Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Share Price
$0.7025917
Last synced: 2026-11-10
Market Cap
$75.01M
Change (1 day)
2.78%
Change (1 year)
-35.95%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ReproCELL Incorporated (4978)
Category
Healthcare
Operating Margin for ReproCELL Incorporated (4978)
Operating Margin as of November 2026 TTM: -38.19%
According to ReproCELL Incorporated's latest financial reports, its current operating margin (TTM) is -38.19%. At the end of 2025 the company had an operating margin of -4.38%.
Operating Margin history for ReproCELL Incorporated from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -38.19% | 771.92% |
| 2025 | -4.38% | -74.04% |
| 2024 | -16.87% | 39.88% |
| 2023 | -12.06% | -58.36% |
| 2022 | -28.96% | -64.46% |
| 2021 | -81.48% | 7.56% |
| 2020 | -75.75% | 5.56% |
| 2019 | -71.76% | -35.21% |
| 2018 | -110.75% | 47.51% |
| 2017 | -75.08% | -21.85% |
| 2016 | -96.07% | -26.46% |
| 2015 | -130.63% | 545.41% |
| 2014 | -20.24% | 88.28% |
| 2013 | -10.75% | -65.01% |
| 2012 | -30.72% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.01% |
US
|
|
| -149.01% | -96.10% |
US
|
|
| 25.57% | -100.67% |
AU
|
|
| 31.23% | -100.82% |
BE
|
|
| 29.35% | -100.77% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about ReproCELL Incorporated's operating margin
What is ReproCELL Incorporated's operating margin?
ReproCELL Incorporated's operating margin is -38.19%, as of Nov 2026.
What was ReproCELL Incorporated's operating margin in 2025?
In 2025, ReproCELL Incorporated's operating margin was -4.38%, compared with -16.87% in 2024.
How has ReproCELL Incorporated's operating margin changed since 2020?
From 2020 to 2025, ReproCELL Incorporated's operating margin was highest in 2025 (-4.38%) and lowest in 2021 (-81.48%).
How does ReproCELL Incorporated's operating margin compare with similar companies?
ReproCELL Incorporated's operating margin (-38.19%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.